A number of signs point to some promising new and continuing trends for the biotech industry in the year ahead, observers are saying, with myriad financial opportunities available to companies and investors alike. (BioWorld Today)

MedImmune Inc. acquired rights to a target for certain inflammatory diseases from Japan Tobacco (JT) Inc., with a lead compound the deal's centerpiece. (BioWorld Today)

MedImmune Inc. acquired rights to a target for certain inflammatory diseases from Japan Tobacco (JT) Inc., with a lead compound the deal's centerpiece. (BioWorld Today)